MacroGenics Future Growth
Future criteria checks 0/6
MacroGenics's revenue and earnings are forecast to decline at 14.3% and 23.9% per annum respectively. EPS is expected to decline by 14.2% per annum. Return on equity is forecast to be -127.5% in 3 years.
Key information
-23.9%
Earnings growth rate
-14.2%
EPS growth rate
| Biotechs earnings growth | 42.4% |
| Revenue growth rate | -14.3% |
| Future return on equity | -127.5% |
| Analyst coverage | Good |
| Last updated | 07 Nov 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 93 | -152 | -177 | -100 | 5 |
| 12/31/2025 | 78 | -152 | -147 | -112 | 9 |
| 12/31/2024 | 160 | -61 | -61 | -29 | 9 |
| 9/30/2024 | 141 | -98 | -62 | -58 | N/A |
| 6/30/2024 | 41 | -136 | -157 | -153 | N/A |
| 3/31/2024 | 43 | -23 | -114 | -111 | N/A |
| 12/31/2023 | 59 | -9 | -80 | -78 | N/A |
| 9/30/2023 | 121 | 50 | -22 | -21 | N/A |
| 6/30/2023 | 152 | 7 | 3 | 5 | N/A |
| 3/31/2023 | 165 | -91 | -45 | -42 | N/A |
| 12/31/2022 | 152 | -120 | -91 | -87 | N/A |
| 9/30/2022 | 93 | -191 | -175 | -171 | N/A |
| 6/30/2022 | 67 | -219 | -182 | -176 | N/A |
| 3/31/2022 | 72 | -217 | -179 | -172 | N/A |
| 12/31/2021 | 77 | -202 | -150 | -144 | N/A |
| 9/30/2021 | 116 | -146 | -103 | -95 | N/A |
| 6/30/2021 | 119 | -129 | -113 | -106 | N/A |
| 3/31/2021 | 108 | -136 | -102 | -97 | N/A |
| 12/31/2020 | 105 | -130 | -118 | -112 | N/A |
| 9/30/2020 | 77 | -158 | -148 | -144 | N/A |
| 6/30/2020 | 78 | -167 | -140 | -136 | N/A |
| 3/31/2020 | 68 | -152 | -152 | -148 | N/A |
| 12/31/2019 | 64 | -152 | -139 | -134 | N/A |
| 9/30/2019 | 55 | -166 | -127 | -123 | N/A |
| 6/30/2019 | 57 | -155 | -150 | -143 | N/A |
| 3/31/2019 | 65 | -167 | -164 | -152 | N/A |
| 12/31/2018 | 60 | -171 | -178 | -153 | N/A |
| 9/30/2018 | 197 | -21 | -49 | -14 | N/A |
| 6/30/2018 | 178 | -34 | N/A | -9 | N/A |
| 3/31/2018 | 160 | -32 | N/A | 18 | N/A |
| 12/31/2017 | 158 | -20 | N/A | 14 | N/A |
| 9/30/2017 | 10 | -160 | N/A | -126 | N/A |
| 6/30/2017 | 12 | -147 | N/A | -45 | N/A |
| 3/31/2017 | 91 | -66 | N/A | -47 | N/A |
| 12/31/2016 | 92 | -59 | N/A | -44 | N/A |
| 9/30/2016 | 95 | -52 | N/A | -40 | N/A |
| 6/30/2016 | 106 | -34 | N/A | -97 | N/A |
| 3/31/2016 | 32 | -96 | N/A | -89 | N/A |
| 12/31/2015 | 101 | -20 | N/A | -14 | N/A |
| 9/30/2015 | 98 | -11 | N/A | -10 | N/A |
| 6/30/2015 | 102 | 1 | N/A | -16 | N/A |
| 3/31/2015 | 104 | 10 | N/A | 5 | N/A |
| 12/31/2014 | 48 | -38 | N/A | -33 | N/A |
| 9/30/2014 | 57 | -20 | N/A | -14 | N/A |
| 6/30/2014 | 59 | -15 | N/A | 1 | N/A |
| 3/31/2014 | 62 | 0 | N/A | -4 | N/A |
| 12/31/2013 | 58 | 0 | N/A | -14 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: M55 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: M55 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: M55 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: M55's revenue is expected to decline over the next 3 years (-14.3% per year).
High Growth Revenue: M55's revenue is forecast to decline over the next 3 years (-14.3% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: M55 is forecast to be unprofitable in 3 years.